Foundation Medicine and Agios partnered to develop a diagnostic to identify which cancer patients are most likely to respond to Agios' isocitrate dehydrogenase 1 (IDH1) and IDH2 inhibitors

Agios Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Foundation Medicine Inc.

U.S. / Medical Devices and Diagnostics

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced